Company news
Cannabis Bioscience International Holdings, Inc. news in 2026
Cannabis Bioscience International Holdings, Inc.'s news releases, calls and decks from 2026, newest first.
CBIH Announces Expanded Research Strategy at the Intersection of Endocannabinoid Science and Biological Medicine
October 19, 2026
CBIH Unveils Cannabinoid-Based Intranasal Platform for Alzheimer's Research
July 20, 2026
Years of Preparation. One Regulatory Approval. Commercial Launch Begins: CBIH Receives Texas License for Consumable Hemp Products
July 15, 2026
CBIH Announces Recognition Initiative Funded Through CEO's Personal Share Holdings
July 6, 2026
Cannabis Bioscience International Holdings Opens New Revenue Pathway with First VitaCookies Licensing Agreement
June 22, 2026
CBIH Announces Patent-Related Scientific Framework for PTSD-Focused Cannabinoid and Psilocybin Research
June 15, 2026
CBIH Advances Strategic Pathway to Bring VitaCookies' Science-Driven Functional Wellness Platform to Texas Consumers
June 8, 2026
CBIH Completes Cannabinoid-Based Melanoma Patent Application Program Focused on Cannabinoid Science and Epigenetic Regulation
June 1, 2026
Cannabis Bioscience International Holdings Seeks Participation in Renewed DEA Marijuana Rescheduling Hearing
May 13, 2026
CBIH Evaluates a Potential Reg A Offering of Approximately $1,000,000 to Enable Commercial Launch, Statewide Educational Expansion, and Protection of Its Patent Portfolio
January 21, 2026
CBIH Puts CMS at the Center of the Board: Formal Coordination with Dr. Mehmet Oz's Team and an "Evidence Sprint 2026" Focused on Grants, Research and Clinical Evidence
January 12, 2026
CBIH Launches Federal and Pharmaceutical Outreach Initiative to Accelerate Medical Cannabis Research in the Schedule III Transition
January 5, 2026